A recombinant humanized monoclonal IgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF). Bevacizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to VEGF. Bevacizumab is produced in a Chinese Hamster Ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin and has a molecular weight of approximately 149 kilodaltons.
Specifications
- Classify
- Protein therapeutics that interfere with a molecule or organism: Cancer
- Therapeutic
- Bevacizumab
- Trade Name
- Bevacizumab
- Function
- Humanized mAb that binds all isoforms of veGFA
- Examples of Clinical Use
- Colorectal cancer, non-small-cell lung cancer
References
- Synonyms
- antiVEGF, bevacizumab
For lab research use only, not for diagnostic, therapeutic or any in vivo human use.
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
Tel: 1-631-381-2994
Fax: 1-631-207-8356
Email: